[go: up one dir, main page]

BRPI0815546A2 - Marcador preditivo para tratamento com inibidor da egfr - Google Patents

Marcador preditivo para tratamento com inibidor da egfr

Info

Publication number
BRPI0815546A2
BRPI0815546A2 BRPI0815546-1A2A BRPI0815546A BRPI0815546A2 BR PI0815546 A2 BRPI0815546 A2 BR PI0815546A2 BR PI0815546 A BRPI0815546 A BR PI0815546A BR PI0815546 A2 BRPI0815546 A2 BR PI0815546A2
Authority
BR
Brazil
Prior art keywords
egfr inhibitor
inhibitor treatment
predictive marker
predictive
marker
Prior art date
Application number
BRPI0815546-1A2A
Other languages
English (en)
Inventor
Paul Delmar
Barbara Klughammer
Verena Lutz
Patricia Mcloughlin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0815546A2 publication Critical patent/BRPI0815546A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0815546-1A2A 2007-08-14 2008-08-07 Marcador preditivo para tratamento com inibidor da egfr BRPI0815546A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07114326 2007-08-14
PCT/EP2008/006514 WO2009021675A1 (en) 2007-08-14 2008-08-07 Predictive marker for egfr inhibitor treatment

Publications (1)

Publication Number Publication Date
BRPI0815546A2 true BRPI0815546A2 (pt) 2015-02-10

Family

ID=39816632

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815546-1A2A BRPI0815546A2 (pt) 2007-08-14 2008-08-07 Marcador preditivo para tratamento com inibidor da egfr

Country Status (10)

Country Link
US (1) US20110312981A1 (pt)
EP (1) EP2188392A1 (pt)
JP (1) JP2010535518A (pt)
KR (1) KR20100037638A (pt)
CN (1) CN101778950A (pt)
AU (1) AU2008286408A1 (pt)
BR (1) BRPI0815546A2 (pt)
CA (1) CA2695070A1 (pt)
MX (1) MX2010001570A (pt)
WO (1) WO2009021675A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013171753A1 (en) * 2012-05-16 2013-11-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of treating and diagnosing diseases using agents that regulate the alternative splicing pathway

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1636380A2 (en) * 2003-05-30 2006-03-22 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
KR101126560B1 (ko) * 2003-05-30 2012-04-05 도꾜 다이가꾸 약제 반응 예측 방법
US8093011B2 (en) * 2005-03-16 2012-01-10 Haley John D Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2007072225A2 (en) * 2005-12-01 2007-06-28 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2007067500A2 (en) * 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors

Also Published As

Publication number Publication date
EP2188392A1 (en) 2010-05-26
US20110312981A1 (en) 2011-12-22
WO2009021675A1 (en) 2009-02-19
KR20100037638A (ko) 2010-04-09
AU2008286408A1 (en) 2009-02-19
MX2010001570A (es) 2010-03-15
JP2010535518A (ja) 2010-11-25
CN101778950A (zh) 2010-07-14
CA2695070A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
CY2017016I1 (el) Αναστολεις πρωτεασωματος
BRPI0806898A2 (pt) Inibidores de mek
BRPI0814797A2 (pt) Inibidores dna-pk
EP2079385A4 (en) BREAST CHARACTERISTICS SUBSCRIBERS
BRPI0821129A2 (pt) Métodos para a inibição de cicatrização
EP2115162A4 (en) Adrb2 cancer markers
BRPI0812040A2 (pt) Indicações para terapia de anti-il-i-beta
EP2177529A4 (en) NEW SECRETASE HEMMER
BRPI0815415A2 (pt) Marcador preditivo para tratamento inibidor de egfr
ATE522533T1 (de) Pyrazolopyrimidinonkinaseinhibitor
BRPI0814257A2 (pt) marcador preditivo para o tratamento do inibidor de egfr
BRPI0815545A2 (pt) Marcadores preditivos para o tratamento com inibidores de egfr
BRPI0817361A2 (pt) Marcador preditivo para tratamento com inibidor de egfr
BRPI0814354A2 (pt) Marcador preditivo para tratamento com inibidor de egfr
BRPI0715729A2 (pt) inibidores para glyt-1
BRPI0815414A2 (pt) Marcador para o tratamento com inibidor de egfr
BRPI0812105A2 (pt) Neramexano para o tratamento de nistagmo
BRPI0815546A2 (pt) Marcador preditivo para tratamento com inibidor da egfr
ES2395881T9 (es) Marcador predictivo para el tratamiento de inhibidor de EGFR
FI20075320A0 (fi) Uusia käyttökelpoisia inhibiittoreita
BRPI0815372A2 (pt) marcador preditivo para o tratamento com inibidor do egfr
ES1067107Y (es) Entresuela para calzado
BRPI0821270A2 (pt) Métodos para a inibição de cicatrização
ES1065835Y (es) Caperuza para cetreria
ES1064561Y (es) Electrovalvula para grifo

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]